Consumers sound alarm: state price controls will limit access without lowering patient costs
A new survey demonstrates that a majority of consumers want health plans to lower out-of- pocket costs, but are concerned state government price controls will harm access and not reduce costs
Do Cost-Effectiveness Analyses Account for Drug Genericization?
The omission of assumptions about genericization means that CEAs may misrepresent the long run opportunity costs for drugs. The field needs clearer guidance for when CEAs should account for genericization, and for the inclusion of other price dynamics that might influence a drug’s cost-effectiveness.